Biogen Completes Acquisition of Human Immunology Biosciences
July 02, 2024 09:16 ET
|
Biogen Inc.
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
June 29, 2024 10:31 ET
|
Halper Sadeh LLC
NEW YORK, June 29, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024 07:30 ET
|
Biogen Inc.
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024 05:27 ET
|
Novartis Pharma AG
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the...
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto...
Novartis tender offer for MorphoSys AG commences
April 11, 2024 04:20 ET
|
Novartis Pharma AG
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG...
[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 04, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer...
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
February 05, 2024 16:45 ET
|
Novartis Pharma AG
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight
January 01, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight ...